Sinogen s Relocation Celebration and New Cancer Therapies Summit Forum are successfully held.

Sinogen's Relocation Celebration and New Cancer Therapies Summit Forum were successfully held at the new site of Sinogen on November 27, 2021.

Guests present included not only academicians and Yangtze River scholars, but also pharmaceutical industry professionals and clinical experts, but also company shareholders and representatives of many investment institutions. All the guests participated in and witnessed the happy moment of ribbon cutting ceremony for Sinogen relocation. We jointly witnessed the successful upgrade of Sinogen from a pre-clinical biotechnology development enterprise to a clinical stage biopharmaceutical enterprise. Sinogen established a high-standard biologics production and R&D base in the Scientific and Technological Enterprise Accelerator in Guangzhou Development Zone, which can well meet the production and supply needs of oncolytic bacteria products required for clinical trials.

During the full-day forum, experts and scholars conducted in-depth discussions around Sinogen's core product SGN1 (oncolytic bacterium) from multiple perspectives in antitumor drug discovery including clinical development strategy, clinical design and control, indication selection, pharmacological and toxicological analysis, and patient case analysis, to provide suggestions for the development of Sinogen.

Thanks to the strong support and assistance from the government and various sectors of the society, we believe that under the guidance and leadership of our board of directors and management, Sinogen will continue to accelerate its development and growth; achieve the dual goals of enterprise listing and product launch as soon as possible, and continuously develop innovative drugs in China for China and the world!